Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib.
about
Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura.Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib.Mechanisms of Autoantibody-Induced Pathology.Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model.
P2860
Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib.
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Rituximab-refractory thromboti ...... t not subcutaneous bortezomib.
@ast
Rituximab-refractory thromboti ...... t not subcutaneous bortezomib.
@en
type
label
Rituximab-refractory thromboti ...... t not subcutaneous bortezomib.
@ast
Rituximab-refractory thromboti ...... t not subcutaneous bortezomib.
@en
prefLabel
Rituximab-refractory thromboti ...... t not subcutaneous bortezomib.
@ast
Rituximab-refractory thromboti ...... t not subcutaneous bortezomib.
@en
P2093
P2860
P356
P1433
P1476
Rituximab-refractory thromboti ...... t not subcutaneous bortezomib.
@en
P2093
Craig Freyer
Elizabeth Griffiths
Eunice S Wang
James E Thompson
Joanne Becker
Priyank P Patel
P2860
P304
P356
10.1111/TRF.13465
P577
2016-01-18T00:00:00Z